DUBLIN--(BUSINESS WIRE)--The "Pulmonary Arterial Hypertension (PAH): Drug Development Pipeline Study, H1 2018" report has been added to ResearchAndMarkets.com's offering.
The report provides detailed analysis of Pulmonary Arterial Hypertension (PAH) pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Pulmonary Arterial Hypertension (PAH) report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Pulmonary Arterial Hypertension (PAH) industry.
The most comprehensive pipeline review Pulmonary Arterial Hypertension (PAH) Drug Development Pipeline Study provides in-depth analysis and update information on Pulmonary Arterial Hypertension (PAH) pipeline drugs. Current status of all the drugs in the Pulmonary Arterial Hypertension (PAH) pipeline is provided in the research work.
Executive Summary:
- Pulmonary Arterial Hypertension pipeline comprises of 53 drugs under development as of March 2018. Of these, 15 drugs are in Phase 1 and 9 drugs in phase 2, 5 drugs in Phase 3. Further, 19 drugs are in Pre-clinical stage and 4 drugs in research phase. One drug is in pre-registration stage.
- 60 companies are developing the pipeline for Pulmonary Arterial Hypertension. Of this, MORPHOGEN-IX Limited, Mifcare.ca, Galectin Therapeutics Inc, and GlaxoSmithKline Pharmaceuticals Ltd have highest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is prostacyclin analogue.
- Nine compounds have been awarded orphan drug status for PAH.
Products Mentioned:
- ABI-009
- acebilustat
- Aironite
- APT-102
- AV-353
- Bardoxolone Methyl
- Beraprost 314d
- Beraprost 314d and treprostinil
- BIA 5-1058
- BMP9
- C21
- CAM 2043
- CAP 1002
- CXA-10
- GM CT-01
- GMA302
- GR MD-02
- GSK 2256098
- GSK 2586881
- PB1046
- PK10453
- PK10571
- PT2567
- QCC 374
- R197
- Ralinepag
- SUD-004
- tacrolimus
- Tiprelestat
- tocilizumab
- TR-422
- Treprostinil PatchPump
- treprostinil prodrug transdermal
- Treprostinil Technosphere
- Udenafil
Companies Mentioned
- APT Therapeutics, Inc.
- AVEO Pharmaceuticals Inc.
- Aerogen Pharma Limited
- Arena Pharmaceuticals Inc.
- Asklepion Pharmaceuticals, LLC
- Bial-Portela & Ca. S.A
- Biogen, Inc.
- Bristol-Myers Squibb Co
- Complexa Inc
- Corsair Pharma, Inc.
- Galectin Therapeutics Inc
- GenThera
- GlaxoSmithKline Pharmaceuticals Ltd
- Gmax Biopharm Biomedical Engineering Co., Ltd.
- Insmed, Inc.
- Invent Pharmaceuticals, Inc.
- Japan Tobacco Inc
- Johnson & Johnson
- Karos Pharmaceuticals, Inc
- Mezzion Pharma Co Ltd
- Mifcare.ca
- Nippon Shinyaku
- Nissan Chemical Industries
- Novartis AG
- Novartis International AG
- Peloton Therapeutics Inc
- PhaseBio Pharmaceuticals, Inc
- Proteo Biotech AG
- Selten Pharma, LLC.
- Serodus ASA
- SteadyMed Therapeutics Inc
- Suda Ltd
- Takeda Pharmaceutical Co Ltd
- Tritech Biopharmaceuticals Co Ltd
For more information about this report visit https://www.researchandmarkets.com/research/bjpnst/pulmonary?w=4
